Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Leukemia 10Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myeloid, Acute 7Blast Crisis 7Neoplasms 6Leukemia, Myeloid, Accelerated Phase 6Myeloproliferative Disorders 5Carcinoma, Non-Small-Cell Lung 5Neoplasms by Histologic Type 4Leukemia, Myeloid 4Hematologic Diseases 4Bone Marrow Diseases 4Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myelomonocytic, Chronic 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2Breast Neoplasms 2Thyroid Neoplasms 1Thrombocytosis 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Piebaldism 1

Interventions

ponatinib 1Telemedicine 1Acceptance and Commitment Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Malignant Hepatobiliary Neoplasm × ponatinib × Clear all
NCT02265341 2020-11-25

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Mayo Clinic

Phase 2 Completed
12 enrolled 11 charts
Gastrointestinal

Malignant Hepatobiliary Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡